Autres langues Joinn Laboratories(China)Co.,Ltd. Hong Kong S.E.

Actions

6127

CNE100004BP3

Recherche biotechnologique et médicale

Temps Différé Hong Kong S.E. 09:30:50 10/09/2026			Varia. 5j.	Varia. 1 janv.
21,80 ^HKD	-3,71%		-7,71%	+5,83%

28/08	Le bénéfice attribuable de Joinn Laboratories bondit au S1 ; chiffre d'affaires en hausse	MT
28/08	Joinn Laboratories (China) Co., Ltd. publie ses résultats pour le premier semestre clos le 30 juin 2026	CI

Autres langues

28/08	Joinn Laboratories' H1 Attributable Profit Surges; Revenue Up
28/08	Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026
17/07	Joinn Laboratories Co., Ltd. Announces Changes of Joint Company Secretary, Effective July 17, 2026
17/07	Joinn Laboratories Attributes Recent Stock Surge to Robust Earnings Forecast; Hong Kong Shares Fall 7%
14/07	Joinn Laboratories Forecasts Up to 1,377% Surge in H1 Profit
14/07	Joinn Laboratories(China)Co.,Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Half Year Ended 30 June 2026
25/06	Xbrane Biopharma AB And JOINN Biologics US Inc. Partner To Develop Xdarzane
11/06	Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)
04/06	Joinn Laboratories Co., Ltd. Announces Executive Changes
04/06	Joinn Laboratories Co., Ltd. Approves Cash Dividend for the Financial Year Ended December 31, 2025, Payable by August 4, 2026
30/04	Joinn Laboratories Grants 1.4 Million Award Shares Under 2022 Scheme
30/04	Joinn Laboratories' Profit Surges 480% in Q1
29/04	Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
31/03	Joinn Laboratories' Attributable Profit Soars 302% in 2025
30/03	Joinn Laboratories(China)Co.,Ltd. Proposes Final Dividend for the Year Ended December 31, 2025, Payable on August 4, 2026
30/03	Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
17/03	Joinn Laboratories Subsidiary Purchases Asset Management Plan from CITIC
17/03	Joinn Laboratories China's shareholders plan to unload stakes
16/03	Joinn Laboratories China shareholders plan to cut stakes
21/01	Joinn Laboratories Expects 2025 Profit to More Than Triple Year on Year
21/01	Joinn Laboratories Forecasts Up to 371% Jump in 2025 Profit
20/01	Joinn Laboratories China sees 2025 revenue RMB1.57 billion to RMB1.74 billion
20/01	Joinn Laboratories(China)Co.,Ltd. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025
15/12	Joinn Laboratories(China)Co.,Ltd.(SHSE:603127) added to Shanghai Stock Exchange Health Care Sector Index
05/12	Joinn Laboratories(China)Co.,Ltd. Enters into Staidson Research and Development Service Framework Agreement